首页> 外文期刊>The Open Women s Health Journal >Diagnosis of Vulvovaginal Candidiasis and Effectiveness of CombinedTopical Treatment with Nystatin: Results of a Non-Interventional Study in973 Patients
【24h】

Diagnosis of Vulvovaginal Candidiasis and Effectiveness of CombinedTopical Treatment with Nystatin: Results of a Non-Interventional Study in973 Patients

机译:外阴念珠菌病的诊断和制霉菌素联合局部治疗的有效性:973例患者的非干预性研究结果

获取原文
       

摘要

Introduction & Objectives: This non-interventional study was performed in 231 gynaecological surgeries in orderto assess current routine diagnostic practice as well as present effectiveness and tolerability of a combined topicaltreatment with nystatin in patients with uncomplicated vulvovaginal candidiasis (VVC).Methods: Naive or insufficiently treated VVC patients received a combined topical antimycotic treatment§. Diagnosticprocedures were documented. Cardinal disease symptoms and dosage regimens were recorded before and after therapy.Investigators and patients rated treatment effectiveness and tolerance. Adverse events and withdrawals were documented.Results: All 1,011case reports were included in the safety analysis; thereof 973 cases in the efficacy analysis. Based on diagnosesconform to guidelines 74.7% of the patients had a primary infection while 24.9% were experiencing a relapse.After a treatment period of 6 days (median), individual symptoms had ceased in up to 81.9%. Complete healing wasachieved in 63.1% (vulva) and 65.4% (vagina). Investigators rated therapy outcome as “healing/significant improvement”in 90.0% (vulva) and 88.2% (vagina), and tolerance “as very good/good” in 97.4%.Conclusions: Routine diagnosis of VVC predominantly corresponds to relevant guidelines. Combined intra- and perivaginaltherapy of VVC with nystatin is an effective, safe and cost-conscious treatment option. Nystatin has not lost its effectivenessover the years. §Nystatin cream and vaginal tablets (Biofanal? 100.000 IU combination package), Dr. R. Pfleger GmbH, D-96045 Bamberg,Germany
机译:简介与目的:这项非干预性研究是在231例妇科手术中进行的,目的是评估当前的常规诊断方法,以及使用制霉菌素联合局部用奈斯汀治疗对单纯性阴道阴道念珠菌病(VVC)患者的有效性和耐受性。治疗的VVC患者接受了联合局部抗真菌药治疗§。诊断程序已记录。治疗前后记录心脏疾病的症状和用药方案,研究者和患者对治疗的有效性和耐受性进行了评估。结果:安全性分析包括所有1,011例病例报告。其中973例在疗效分析中。根据诊断符合指导原则,有74.7%的患者是原发感染,而24.9%的患者正在复发。经过6天(中位数)的治疗后,个体症状的缓解率高达81.9%。完全治愈率达到63.1%(外阴)和65.4%(阴道)。研究者将治疗结果评为“愈合/明显好转”为90.0%(外阴)和88.2%(阴道),耐受性为“很好/很好”,为97.4%。结论:VVC的常规诊断主要符合相关指南。 VVC与制霉菌素联合阴道内和阴道阴道治疗是一种有效,安全且具有成本意识的治疗选择。制霉菌素多年来一直没有失去效力。抑霉菌素乳膏和阴道片(Biofanal?100.000 IU组合包装),R。Pfleger GmbH博士,D-96045 Bamberg,德国

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号